{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:17Z","timestamp":1792153997442,"version":"4.4.0"},"reference-count":124,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PRIN 2022","award":["C53D23004490001"],"award-info":[{"award-number":["C53D23004490001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>In the last three decades, 2-oxazolidinones have emerged as an important class of inhibitors of bacterial protein synthesis, effective in the treatment of multidrug-resistant (MDR) bacterial infections. From a public health perspective, the importance of 2-oxazolidinones is related to the treatment of tuberculosis (TB), primarily MDR-TB and extensively drug-resistant XDR-TB. Linezolid, the first oxazolidinone antibiotic approved by FDA, is still used in therapy despite common adverse events, such as myelosuppression and serotonergic toxicity, as well as the increasing percentage of linezolid-resistant bacteria (Staphylococcus aureus, enterococci and methicillin-resistant S. aureus). Tedizolid phosphate was the second commercially available oxazolidinone antibiotic approved, followed by other oxazolidinones (contezolid, radezolid, ranbezolid, sutezolid, delpazolid, cadazolid, TBI-233 and MK-7762) that are in clinical study. Contezolid is approved in China and cadazolid has entered phase III clinical trials. This comprehensive review intends to provide an overview of the compounds belonging to this class already in use in therapy and\/or clinical studies and to portray the most significant and recent outcomes regarding new oxazolidinones under study. Three literature databases, i.e., PubMed\/MEDLINE, Google Scholar and Scopus, were used for the literature search, particularly focusing on the last five years, and screened using different keywords. The design of new drugs belonging to this class may be of considerable interest to researchers and clinicians, contributing to the discovery of new antibiotics that retain antibacterial activity but have fewer side effects.<\/jats:p>","DOI":"10.3390\/ph19030432","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:05:44Z","timestamp":1772795144000},"page":"432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current Status and Perspectives of Antibacterial Agents Belonging to 2-Oxazolidinones"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1386-3601","authenticated-orcid":false,"given":"Jessica","family":"Ceramella","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-838X","authenticated-orcid":false,"given":"Annaluisa","family":"Mariconda","sequence":"additional","affiliation":[{"name":"Department of Basic and Applied Sciences, University of Basilicata, Via dell\u2019Ateneo Lucano, 10, 85100 Potenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-7118","authenticated-orcid":false,"given":"Domenico","family":"Iacopetta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Marra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7420-4706","authenticated-orcid":false,"given":"Alessia","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Drug Sciences, University of Bari \u201cAldo Moro\u201d, Via Orabona, 4, 70126 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-5730","authenticated-orcid":false,"given":"Paola","family":"Checconi","sequence":"additional","affiliation":[{"name":"Department for the Promotion of Human Sciences and Quality of Life, San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy"},{"name":"Laboratory of Microbiology, IRCCS San Raffaele Roma, Via di Val Cannuta 247, 00166 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-2103","authenticated-orcid":false,"given":"Stefano","family":"Aquaro","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, Piazzale Salvatore Tommasi, 1, Blocco 11, Coppito, 67010 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7419-8780","authenticated-orcid":false,"given":"Carmela","family":"Saturnino","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Basilicata, Via dell\u2019Ateneo Lucano, 10, 85100 Potenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7685-1093","authenticated-orcid":false,"given":"Pasquale","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biology \u201cA. Zambelli\u201d, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-8931","authenticated-orcid":false,"given":"Maria Stefania","family":"Sinicropi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1021\/acs.orglett.5c01410","article-title":"Beyond 2-Oxazolidinones: Access to N-Unsubstituted Six-and Seven-Membered Analogues Using CO2 and Superbase Catalyst","volume":"27","author":"Mannisto","year":"2025","journal-title":"Org. Lett."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568005014606099","article-title":"The discovery of linezolid, the first oxazolidinone antibacterial agent","volume":"1","author":"Ford","year":"2001","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/jms.jms_156_24","article-title":"Oxazolidinones: Mechanism of action and molecular characterization of resistance mechanisms in staphylococci","volume":"39","author":"Sangita","year":"2025","journal-title":"J. Med. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Buckley, M.E., Ndukwe, A.R.N., Nair, P.C., Rana, S., Fairfull-Smith, K.E., and Gandhi, N.S. (2023). Comparative Assessment of Docking Programs for Docking and Virtual Screening of Ribosomal Oxazolidinone Antibacterial Agents. Antibiotics, 12.","DOI":"10.3390\/antibiotics12030463"},{"key":"ref_5","first-page":"81","article-title":"Therapeutic Potential of Oxazolidine Derivative: A Critical Review of Their Biological Activities","volume":"18","author":"Muhubhupathi","year":"2025","journal-title":"Asian J. Res. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jac\/dkw450","article-title":"Linezolid: A Promising Option in the Treatment of Gram-Positives","volume":"72","author":"Rahbar","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(01)06964-1","article-title":"Oxazolidinone antibiotics","volume":"358","author":"Diekema","year":"2001","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1021\/jm501045e","article-title":"Design, Synthesis, and Structure\u2013Activity and Structure\u2013Pharmacokinetic Relationship Studies of Novel [6,6,5] Tricyclic Fused Oxazolidinones Leading to the Discovery of a Potent, Selective, and Orally Bioavailable FXa Inhibitor","volume":"57","author":"Xue","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Miranda, I.L., Lopes, \u00cd.K., Diaz, M.A., and Diaz, G. (2016). Synthesis Approaches to (\u2212)-Cytoxazone, a Novel Cytokine Modulator, and Related Structures. Molecules, 21.","DOI":"10.3390\/molecules21091176"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115239","DOI":"10.1016\/j.ejmech.2023.115239","article-title":"Oxazolidinone: A Promising Scaffold for the Development of Antibacterial Drugs","volume":"250","author":"Yuan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1039\/D2MD00415A","article-title":"Oxazolidinones as Versatile Scaffolds in Medicinal Chemistry","volume":"14","author":"Fernandes","year":"2023","journal-title":"RSC Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135630","DOI":"10.1016\/j.molstruc.2023.135630","article-title":"Oxazolidinones: Are They Only Good for the Discovery of Antibiotics? A Worm\u2019s Eye View","volume":"1286","author":"Pathania","year":"2023","journal-title":"J. Mol. Struct."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhou, W., Wang, Q., Nie, W., Shi, W., Yang, Y., Qi, W., Lu, Y., and Chu, N. (BMC Infect. Dis., 2026). Acquired Linezolid Resistance in DR-TB: Genotype-Phenotype Discordance and Molecular Heterogeneity in a Retrospective Cohort, BMC Infect. Dis., in press.","DOI":"10.1186\/s12879-026-12869-8"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chen, Y., Chen, X., Xu, H., Shen, H., Liu, X., Wan, F., Han, Y., Song, X., Li, J., and Du, H. (Emerg. Microb. Infect., 2026). The Emergence and Biological Characteristics of Linezolid-Resistant Clostridioides difficile Isolates in the Asia-Pacific Region, Emerg. Microb. Infect., in press.","DOI":"10.1080\/22221751.2026.2627070"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41429-024-00778-4","article-title":"Resistance to Linezolid in Staphylococcus aureus by Mutation, Modification, and Acquisition of Genes","volume":"78","author":"Yang","year":"2025","journal-title":"J. Antibiot."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gopalaswamy, R., and Subbian, S. (Clin. Microbiol. Rev., 2026). The Power of Resistance: Mechanisms of Antimicrobial Resistance in Mycobacterium tuberculosis and its Impact on Tuberculosis Management, Clin. Microbiol. Rev., in press.","DOI":"10.1128\/cmr.00194-25"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e18825","DOI":"10.7717\/peerj.18825","article-title":"The In Vitro Antimicrobial Activity of Linezolid against Unconventional Pathogens","volume":"13","author":"Wang","year":"2025","journal-title":"PeerJ"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fei, Z.T., Huang, W., Zhou, D.P., Yang, Y., Liu, P., Gan, N., He, P.P., Ye, D., Liu, H.R., and Liu, X.H. (2025). Clinical Efficacy of Linezolid in the Treatment of Tuberculous Meningitis: A Retrospective Analysis and Literature Review. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-10874-x"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Bedeni, B., Chong Gan, W., Fuh Ng, H., Fong Ngeow, Y., Rahman, A., Sungai Long, J., and Sungai Long, B. (2023). Mechanisms of Linezolid Resistance in Mycobacteria. Pharmaceuticals, 16.","DOI":"10.3390\/ph16060784"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s10096-021-04311-5","article-title":"Antimicrobial resistance in Clostridioides difficile","volume":"40","author":"Knight","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"103764","DOI":"10.1016\/j.eclinm.2026.103764","article-title":"Intradiscal Linezolid (PP353) Treatment for Chronic Low Back Pain Associated with Modic Change Type 1: An International, First-In-Human, Randomised, Sham Procedure-Controlled, Double-Blind, Phase 1b Clinical Trial","volume":"92","author":"Lassen","year":"2026","journal-title":"eClinicalMedicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"107470","DOI":"10.1016\/j.ijantimicag.2025.107470","article-title":"A New Perspective on the Antimicrobial Mechanism of Linezolid against Staphylococcus aureus Revealed by Proteomics and Metabolomics Analysis","volume":"65","author":"Luo","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chen, R.H., Burke, A., Cho, J.G., Alffenaar, J.W., and Davies Forsman, L. (2024). New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16060818"},{"key":"ref_24","unstructured":"Working Group on New Drugs (2025, September 29). AZD5847. Available online: https:\/\/www.newtbdrugs.org\/pipeline\/compound\/azd5847."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/13543784.6.2.151","article-title":"Oxazolidinone Antibacterial Agents: Development of the Clinical Candidates Eperezolid and Linezolid","volume":"6","author":"Zurenko","year":"1997","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e02199-23","DOI":"10.1128\/spectrum.02199-23","article-title":"Characterization of In Vitro Resistance to Linezolid in Mycobacterium abscessus","volume":"11","author":"Negatu","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Foti, C., Piperno, A., Scala, A., and Giuffr\u00e8, O. (2021). Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects. Molecules, 26.","DOI":"10.3390\/molecules26144280"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e202400432","DOI":"10.1002\/open.202400432","article-title":"Facile Synthesis of Oxazolidinones as Potential Antibacterial Agents","volume":"14","author":"Els","year":"2025","journal-title":"ChemistryOpen"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1749-6632.2011.05962.x","article-title":"Linezolid, the first oxazolidinone antibacterial agent","volume":"1222","author":"Leach","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1021\/jm800038g","article-title":"Linezolid (Zyvox), the First Member of a Completely New Class of Antibacterial Agents for Treatment of Serious Gram-positive Infections","volume":"51","author":"Brickner","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116326","DOI":"10.1016\/j.ejmech.2024.116326","article-title":"Recent Advances in the Exploration of Oxazolidinone Scaffolds from Compound Development to Antibacterial Agents and Other Bioactivities","volume":"269","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s10822-025-00634-z","article-title":"Exploring Oxazolidinone Scaffolds for Future Antibiotics: Synthesis and Computational Insights with DFT, Docking, ADME and MD Simulation","volume":"39","author":"Soni","year":"2025","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"104944","DOI":"10.1016\/j.etap.2026.104944","article-title":"N-acetylcysteine Reduces Incidence and Duration of Linezolid-Associated Thrombocytopenia in Critically Ill Patients: A Randomized Controlled Trial","volume":"122","author":"Abdeltawab","year":"2026","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40249-023-01107-x","article-title":"Global Prevalence of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis","volume":"12","author":"Salari","year":"2023","journal-title":"Infect. Dis. Poverty"},{"key":"ref_35","unstructured":"World Health Organization (2022). WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment-Drug-Resistant Tuberculosis Treatment, 2022 Update, World Health Organization."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc1500286","article-title":"Linezolid for XDR-TB\u2014Final Study Outcomes","volume":"373","author":"Lee","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/cid\/ciad051","article-title":"Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial","volume":"76","author":"Solans","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5588\/ijtldopen.24.0360","article-title":"Efficacy and Safety Data on Pretomanid for Drug-Resistant TB","volume":"2","author":"Thuy","year":"2025","journal-title":"IJTLD Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013Pretomanid\u2013Linezolid Regimens for Drug-Resistant Tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis","volume":"387","author":"Berry","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_42","unstructured":"World Health Organization (2022). Key Updates to the Treatment of Drug-Resistant Tuberculosis: Rapid Communication, June 2024, World Health Organization."},{"key":"ref_43","unstructured":"Bidell, M.R. (2017). Tedizolid. Kucers\u2019 the Use of Antibiotics, CRC Press."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40262-021-01099-7","article-title":"Pharmacokinetics and pharmacodynamics of tedizolid","volume":"61","author":"Iqbal","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lan, S.H., Lin, W.T., Chang, S.P., Lu, L.C., Chao, C.M., Lai, C.C., and Wang, J.H. (2019). Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis. Antibiotics, 8.","DOI":"10.3390\/antibiotics8030137"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"177458","DOI":"10.1016\/j.ejphar.2025.177458","article-title":"Tedizolid for Osteoarticular Infections: Evaluation of the Published Evidence","volume":"998","author":"Athanasiou","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fong, I.W. (2023). New Oxazolidinone: Tedizolid. New Antimicrobials: For the Present and the Future, Springer International Publishing.","DOI":"10.1007\/978-3-031-26078-0_6"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1038\/s41598-024-55916-7","article-title":"In Vitro Activity of Tedizolid against 43 Species of Nocardia Species","volume":"14","author":"Toyokawa","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2292077","DOI":"10.1080\/22221751.2023.2292077","article-title":"Differences in Oxazolidinone Resistance Mechanisms and Small Colony Variants Emergence of Staphylococcus aureus Induced in an In Vitro Resistance Development Model","volume":"13","author":"Staudacher","year":"2024","journal-title":"Emerg. Microb. Infect."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jiac.2024.01.002","article-title":"Efficacy and Side-Effect Profile of Tedizolid in the Treatment of Streptococcal Toxic Shock Syndrome Due to Clindamycin-resistant Streptococcus pyogenes: A Case Report","volume":"30","author":"Yokota","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"dlag004","DOI":"10.1093\/jacamr\/dlag004","article-title":"Optimizing Tedizolid Dosing in Cerebral Nocardiosis: Clinical Impact of Direct Unbound Concentration Measurement and Population PK Modelling in Two Cases","volume":"8","author":"Margaux","year":"2026","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s15010-024-02287-w","article-title":"Advances in Contezolid: Novel Oxazolidinone Antibacterial in Gram-Positive Treatment","volume":"52","author":"Zhang","year":"2024","journal-title":"Infection"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e04627-22","DOI":"10.1128\/spectrum.04627-22","article-title":"In Vitro Activities of Contezolid (MRX-I) against Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis","volume":"11","author":"An","year":"2023","journal-title":"Microbiol. Spect."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"118025","DOI":"10.1016\/j.bmc.2024.118025","article-title":"Structural Toxicity Relationship (STR) of Linezolid to Mitigate Myelosuppression and Serotonergic Toxicity","volume":"118","author":"Shaikh","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.2147\/IDR.S468543","article-title":"Plasma Concentrations of Contezolid and Its Efficacy and Safety in Elderly Patients with Multidrug-Resistant Tuberculosis and Renal Insufficiency","volume":"17","author":"Ma","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Liu, W., He, T., Qin, H., and Zhang, P. (2025). Concentration of Contezolid in Cerebrospinal Fluid and Serum in a Patient with Renal Allograft Tuberculosis and Tuberculous Meningoencephalitis. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-12036-5"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2147\/IDR.S516991","article-title":"Safety and Tolerability of Contezolid Versus Linezolid for Short-Term Treatment of Rifampicin-Resistant Pulmonary Tuberculosis: A Randomized Controlled Study","volume":"18","author":"Wang","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e01828-24","DOI":"10.1128\/aac.01828-24","article-title":"Triple Antimicrobial Combinations with Potent Synergistic Activity against M. abscessus","volume":"69","author":"Huang","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s40265-021-01576-0","article-title":"Contezolid: First Approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/jac\/dkac073","article-title":"A Phase III Multicentre, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Oral Contezolid versus Linezolid in Adults with Complicated Skin and Soft Tissue Infections","volume":"77","author":"Zhao","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Li, B., Liu, Y., Luo, J., Cai, Y., Chen, M., and Wang, T. (2023). Contezolid, a Novel Oxazolidinone Antibiotic, May Improve Drug-related Thrombocytopenia in Clinical Antibacterial Treatment. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1157437"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41429-025-00825-8","article-title":"Contezolid, a Novel Oxazolidinone Antibiotic, Acts as a Potential Anti-Inflammatory Agent","volume":"78","author":"Liu","year":"2025","journal-title":"J. Antibiot."},{"key":"ref_63","unstructured":"Magro, F. (2017). Radezolid. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, CRC Press. [7th ed.]."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wang, C., Xiong, Y., Bao, C., Wei, Y., Wen, Z., Cao, X., Yu, Z., Deng, X., Li, G., and Deng, Q. (2023). Antibacterial and Anti-biofilm Activity of Radezolid against Staphylococcus aureus Clinical Isolates from China. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1131178"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zheng, J., Chen, Z., Lin, Z., Sun, X., Bai, B., Xu, G., Chen, J., Yu, Z., and Qu, D. (2020). Radezolid Is More Effective Than Linezolid Against Planktonic Cells and Inhibits Enterococcus faecalis Biofilm Formation. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00196"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1107\/S0907444912026236","article-title":"The structure of Enterococcus faecalis Thymidylate Synthase Provides Clues about Folate Bacterial Metabolism","volume":"68","author":"Pozzi","year":"2012","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"103866","DOI":"10.1016\/j.micpath.2019.103866","article-title":"In Vitro Evaluation of the Antibacterial Activities of Radezolid and Linezolid for Streptococcus agalactiae","volume":"139","author":"Zheng","year":"2020","journal-title":"Microb. Pathog."},{"key":"ref_68","unstructured":"Salazar-Austin, N., and Nuermberger, E.L. (2017). Sutezolid. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, CRC Press. [7th ed.]."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dkaf210","article-title":"Cardiac Safety of Bedaquiline, Delamanid and Moxifloxacin Co-administered with or without Varying Doses of Sutezolid or Delpazolid for the Treatment of Drug-susceptible TB","volume":"80","author":"Koele","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S1473-3099(25)00479-7","article-title":"Shaping Opportunities for Future Clinical Trials in Tuberculosis","volume":"26","author":"Mbeya","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119301","DOI":"10.1016\/j.lfs.2021.119301","article-title":"Comprehensive Review on Mechanism of Action, Resistance and Evolution of Antimycobacterial Drugs","volume":"274","author":"Chauhan","year":"2021","journal-title":"Life Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acsmedchemlett.7b00068","article-title":"Discovery of Fluorine-Containing Benzoxazinyl-oxazolidinones for the Treatment of Multidrug Resistant Tuberculosis","volume":"8","author":"Zhao","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(25)00213-0","article-title":"Sutezolid in Combination with Bedaquiline, Delamanid, and Moxifloxacin for Pulmonary Tuberculosis (PanACEA-SUDOCU-01): A Prospective, Open-Label, Randomised, Phase 2b Dose-Finding Trial","volume":"25","author":"Heinrich","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1473-3099(25)00289-0","article-title":"Delpazolid in Combination with Bedaquiline, Delamanid, and Moxifloxacin for Pulmonary Tuberculosis (PanACEA-DECODE-01): A Prospective, Randomised, Open-Label, Phase 2b, Dose-Finding Trial","volume":"25","author":"Minja","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Pluschke, G., and R\u00f6ltgen, K. (2019). Antimicrobial Treatment of Mycobacterium ulcerans Infection. Buruli Ulcer: Mycobacterium ulcerans Disease, Springer.","DOI":"10.1007\/978-3-030-11114-4"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Rasmussen, R., Gibney, K.B., Stinear, T.P., Flegg, J.A., and Campbell, P.T. (2025). Transmission Models of Mycobacterium ulcerans: A Systematic Review. PLoS Negl. Trop. Dis., 19.","DOI":"10.1371\/journal.pntd.0013376"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1021\/acs.jmedchem.1c00480","article-title":"Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs","volume":"64","author":"Zhao","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ndukwe, A.R.N., Qin, J., Wiedbrauk, S., Boase, N.R.B., Fairfull-Smith, K.E., and Totsika, M. (2023). In Vitro Activities of Oxazolidinone Antibiotics Alone and in Combination with C-TEMPO Against Methicillin-Resistant Staphylococcus aureus Biofilms. Antibiotics, 12.","DOI":"10.3390\/antibiotics12121706"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"105546","DOI":"10.1016\/j.micinf.2025.105546","article-title":"Therapeutic Strategies to Combat Staphylococcus aureus Infections in Cystic Fibrosis","volume":"27","author":"Israyilova","year":"2025","journal-title":"Microb. Infect."},{"key":"ref_80","unstructured":"Ndukwe, A.R.N. (2024). Design, Synthesis and Testing of Oxazolidinone Antimicrobials That Target Biofilms. [Ph.D. Thesis, Queensland University of Technology]. Available online: https:\/\/eprints.qut.edu.au\/248139\/."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1021\/acs.jmedchem.4c00558","article-title":"Discovery and Structure\u2013Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection","volume":"67","author":"Rueedi","year":"2024","journal-title":"Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40121-025-01256-6","article-title":"The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review","volume":"15","author":"Chen","year":"2026","journal-title":"Infect. Dis. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1473-3099(18)30614-5","article-title":"Cadazolid for the Treatment of Clostridium difficile Infection: Results of Two Double-Blind, Placebo-Controlled, Non-Inferiority, Randomised Phase 3 Trials","volume":"19","author":"Gerding","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"13860","DOI":"10.1021\/acs.jmedchem.3c01040","article-title":"Strategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1021\/acsinfecdis.4c00025","article-title":"Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities","volume":"10","author":"Boshoff","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1021\/acsmedchemlett.4c00114","article-title":"Design and Synthesis of the Linezolid Bioisosteres to Resolve the Serotonergic Toxicity Associated with Linezolid","volume":"15","author":"Girase","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e01542\u201324","DOI":"10.1128\/aac.01542-24","article-title":"Pharmacokinetics, Tolerability, and Safety of TBI-223, a Novel Oxazolidinone, in Healthy Participants","volume":"69","author":"Lombardi","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1038\/s41467-024-50781-4","article-title":"Dose Optimization of TBI-223 for enhanced Therapeutic Benefit Compared to Linezolid in Antituberculosis Regimen","volume":"15","author":"Strydom","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41591-025-04164-x","article-title":"Discovery and Development of a New Oxazolidinone with Reduced Toxicity for the Treatment of Tuberculosis","volume":"32","author":"Crowley","year":"2026","journal-title":"Nat. Med."},{"key":"ref_90","unstructured":"Bill & Melinda Gates Medical Research Institute (2025, October 06). Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults, ClinicalTrials.gov Identifier: NCT05824091 (2024), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05824091."},{"key":"ref_91","unstructured":"Crowley, B.M. (2021). (WO2021188606), Oxazolidinone Compound and Methods of Use Thereof as an Antibacterial Agent."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"116397","DOI":"10.1016\/j.bmc.2021.116397","article-title":"Synthesis, Microbiological Evaluation and Structure Activity Relationship Analysis of Linezolid Analogues with Different C5-Acylamino Substituents","volume":"49","author":"Matsingos","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_93","unstructured":"(2025, December 11). Clinicaltrials.gov (Expert Search), Available online: https:\/\/clinicaltrials.gov\/expert-search."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/jac\/dkz374","article-title":"Proactive Therapeutic Drug Monitoring (TDM) May Be Helpful in Managing Long-Term Treatment with Linezolid Safely: Findings from a Monocentric, Prospective, Open-Label, Interventional Study","volume":"74","author":"Cojutti","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Shahbazi, F. (Curr. Drug Safety, 2025). Linezolid Related Adverse Effects in Different Populations: A Practical Review, Curr. Drug Safety, in press.","DOI":"10.2174\/0115748863352325250311080624"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1017\/ash.2024.487","article-title":"Linezolid and Tedizolid Adverse Effects: A Review on Serotonin Syndrome, Myelosuppression, Neuropathies, and Lactic Acidosis","volume":"5","author":"Greenfield","year":"2025","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"106843","DOI":"10.1016\/j.ijantimicag.2023.106843","article-title":"Real-World Evaluation of Linezolid-Associated Serotonin Toxicity With and Without Concurrent Serotonergic Agents","volume":"62","author":"Kufel","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"151843","DOI":"10.1016\/j.bbrc.2025.151843","article-title":"Antidepressant- and Anxiolytic-Like Effects of Linezolid in Streptozotocin-Induced Diabetic Mice via Modulation of Brain Serotonin and Plasma Corticosterone Activity","volume":"765","author":"Marathe","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00228-024-03652-2","article-title":"The Effects of Drug-Drug Interaction on Linezolid Pharmacokinetics: A Systematic Review","volume":"80","author":"Xu","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14787210.2024.2448143","article-title":"Optic and Peripheral Neuropathy Associated with Short and Prolonged Administration of Tedizolid: A Review","volume":"23","author":"Katsarou","year":"2025","journal-title":"Exp. Rev. Anti-Infect. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkaf315","article-title":"Peripheral Neuropathy During Long-Term Suppressive Therapy with Tedizolid: A Case Series","volume":"80","author":"Beringheli","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Zhang, W., Cai, X., Hou, R., Guo, J., Ma, Y., Kang, J., and Li, X. (Drug Des. Develop. Ther., 2026). Hematological Safety of Contezolid Versus Linezolid in Stage 5 Chronic Kidney Disease: An Active-Comparator New-User Retrospective Cohort Study, Drug Des. Develop. Ther., in press.","DOI":"10.2147\/DDDT.S576881"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s10096-025-05280-9","article-title":"Efficacy and Safety of Contezolid in the Treatment of Gram-Positive Bacterial Infections in Patients with Hematological Malignancies: A Retrospective Study","volume":"44","author":"Mi","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Stathopoulos, P., Romanos, L.T., Loutradis, C., and Falagas, M.E. (2025). Nephrotoxicity of New Antibiotics: A Systematic Review. Toxics, 13.","DOI":"10.3390\/toxics13070606"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1128\/AAC.49.12.5024-5032.2005","article-title":"In Vitro Activity of Linezolid Against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program","volume":"49","author":"Draghi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/jac\/dky099","article-title":"ZAAPS Programme Results for 2016: An Activity and Spectrum Analysis of Linezolid Using Clinical Isolates from Medical Centres in 42 Countries","volume":"73","author":"Mendes","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.02803-15","article-title":"Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014)","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jgar.2017.10.018","article-title":"The Emerging Problem of Linezolid-Resistant Enterococci","volume":"13","author":"Bi","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Peykov, S., Kirov, B., and Strateva, T. (2025). Linezolid in the Focus of Antimicrobial Resistance of Enterococcus Species: A Global Overview of Genomic Studies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178207"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"147791","DOI":"10.1016\/j.electacta.2025.147791","article-title":"Electrochemical Synthesis of New Linezolid Derivatives of Oxazolidinone Antimicrobial Drug. Reactions and Its Toxicity Mechanism","volume":"546","author":"Miri","year":"2025","journal-title":"Electrochim. Acta"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejmech.2016.07.001","article-title":"Design, Synthesis and Biological Evaluation of Novel Azaspiro Analogs of Linezolid as Antibacterial and Antitubercular Agents","volume":"122","author":"Gadekar","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"127660","DOI":"10.1016\/j.bmcl.2020.127660","article-title":"Design, Synthesis and Antibacterial Evaluation of Novel Oxazolidinone Derivatives Nitrogen-Containing Fused Heterocyclic Moiety","volume":"32","author":"Jiang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Bokhtia, R.M., Girgis, A.S., Ibrahim, T.S., Rasslan, F., Nossier, E.S., Barghash, R.F., Sakhuja, R., Abdel-Aal, E.H., Panda, S.S., and Al-Mahmoudy, A.M.M. (2022). Synthesis, Antibacterial Evaluation, and Computational Studies of a Diverse Set of Linezolid Conjugates. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020191"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"142994","DOI":"10.1016\/j.molstruc.2025.142994","article-title":"Development and Antibacterial Evaluation of Oxazolidinone Derivatives with a Substituted N-methylglycyl C-ring Moiety","volume":"1344","author":"Qu","year":"2025","journal-title":"J. Mol. Struct."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"118144","DOI":"10.1016\/j.bmc.2025.118144","article-title":"Design, Synthesis and Antibacterial Evaluation of Oxazolidinone Derivatives Containing N-methylglycyl or Quaternary Ammonium Salts","volume":"122","author":"Qu","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"130505","DOI":"10.1016\/j.bmcl.2025.130505","article-title":"Synthesis and Evaluation of Novel Oxanthrene Scaffold-Derived Oxazolidinone Antibiotics with Potent Antitubercular Activity and Low Cellular Toxicity","volume":"132","author":"Latterell","year":"2026","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.bmcl.2016.06.019","article-title":"An Evolved Oxazolidinone with Selective Potency against Mycobacterium tuberculosis and Gram Positive Bacteria","volume":"26","author":"Kaushik","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"130359","DOI":"10.1016\/j.bmcl.2025.130359","article-title":"Synthesis and Antibacterial Activity of Novel Benzodioxin-Containing Oxazolidinones Against M. abscessus","volume":"128","author":"Winkelhake","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2479103","DOI":"10.1080\/21505594.2025.2479103","article-title":"Multifaceted Quorum-Sensing Inhibiting Activity of 3-(Benzo[d][1,3]dioxol-4-yl)oxazolidin-2-one Mitigates Pseudomonas aeruginosa Virulence","volume":"16","author":"Wu","year":"2025","journal-title":"Virulence"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1021\/acsmedchemlett.5c00317","article-title":"Novel Oxazolidinone Derivatives Containing Quaternary Ammonium Fragments with Potent Antibacterial Potency","volume":"16","author":"Zheng","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1021\/acs.jmedchem.0c02153","article-title":"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles Against Drug-Resistant Pathogens","volume":"64","author":"Wu","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"16088","DOI":"10.1021\/acs.jmedchem.3c02061","article-title":"Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents Against Drug-Resistant Pathogens","volume":"67","author":"Lu","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.bmc.2007.11.040","article-title":"Synthesis of Novel Oxazolidinone Antimicrobial Agents","volume":"16","author":"Ebner","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.tim.2021.06.006","article-title":"Mycobacterium abscessus","volume":"29","author":"Boudehen","year":"2021","journal-title":"Trends Microbiol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:18:43Z","timestamp":1772795923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":124,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ph19030432"],"URL":"https:\/\/doi.org\/10.3390\/ph19030432","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}